A	a	O	O
novel	novel	O	O
compound	compound	O	O
,	,	O	O
maltolyl	maltolyl	O	O
p-coumarate	p-coumarate	O	O
,	,	O	O
attenuates	attenuates	O	O
cognitive	cognitive	O	B_disease
deficits	deficits	O	I_disease
and	and	O	O
shows	shows	O	O
neuroprotective	neuroprotective	O	O
effects	effects	O	O
in	in	O	O
vitro	vitro	O	O
and	and	O	O
in	in	O	O
vivo	vivo	O	O
dementia	dementia	O	S_disease
models	models	O	O
.	.	O	O

To	to	O	O
develop	develop	O	O
a	a	O	O
novel	novel	O	O
and	and	O	O
effective	effective	O	O
drug	drug	O	O
that	that	O	O
could	could	O	O
enhance	enhance	O	O
cognitive	cognitive	O	O
function	function	O	O
and	and	O	O
neuroprotection	neuroprotection	O	O
,	,	O	O
we	we	O	O
newly	newly	O	O
synthesized	synthesized	O	O
maltolyl	maltolyl	O	O
p-coumarate	p-coumarate	O	O
by	by	O	O
the	the	O	O
esterification	esterification	O	O
of	of	O	O
maltol	maltol	O	O
and	and	O	O
p-coumaric	p-coumaric	O	O
acid	acid	O	O
.	.	O	O

In	in	O	O
the	the	O	O
present	present	O	O
study	study	O	O
,	,	O	O
we	we	O	O
investigated	investigated	O	O
whether	whether	O	O
maltolyl	maltolyl	O	O
p-coumarate	p-coumarate	O	O
could	could	O	O
improve	improve	O	O
cognitive	cognitive	O	B_disease
decline	decline	O	I_disease
in	in	O	O
scopolamine-injected	scopolamine-injected	O	O
rats	rats	O	O
and	and	O	O
in	in	O	O
amyloid	amyloid	O	O
beta	beta	O	O
peptide(1	peptide(1	O	O
-	-	O	O
42)-infused	42)-infused	O	O
rats	rats	O	O
.	.	O	O

Maltolyl	maltolyl	O	O
p-coumarate	p-coumarate	O	O
was	was	O	O
found	found	O	O
to	to	O	O
attenuate	attenuate	O	O
cognitive	cognitive	O	B_disease
deficits	deficits	O	I_disease
in	in	O	O
both	both	O	O
rat	rat	O	O
models	models	O	O
using	using	O	O
passive	passive	O	O
avoidance	avoidance	O	O
test	test	O	O
and	and	O	O
to	to	O	O
reduce	reduce	O	O
apoptotic	apoptotic	O	O
cell	cell	O	O
death	death	O	S_disease
observed	observed	O	O
in	in	O	O
the	the	O	O
hippocampus	hippocampus	O	O
of	of	O	O
the	the	O	O
amyloid	amyloid	O	O
beta	beta	O	O
peptide(1	peptide(1	O	O
-	-	O	O
42)-infused	42)-infused	O	O
rats	rats	O	O
.	.	O	O

We	we	O	O
also	also	O	O
examined	examined	O	O
the	the	O	O
neuroprotective	neuroprotective	O	O
effects	effects	O	O
of	of	O	O
maltolyl	maltolyl	O	O
p-coumarate	p-coumarate	O	O
in	in	O	O
vitro	vitro	O	O
using	using	O	O
SH-SY5Y	sh-sy5y	O	O
cells	cells	O	O
.	.	O	O

Cells	cells	O	O
were	were	O	O
pretreated	pretreated	O	O
with	with	O	O
maltolyl	maltolyl	O	O
p-coumarate	p-coumarate	O	O
,	,	O	O
before	before	O	O
exposed	exposed	O	O
to	to	O	O
amyloid	amyloid	O	O
beta	beta	O	O
peptide(1	peptide(1	O	O
-	-	O	O
42	42	O	O
)	)	O	O
,	,	O	O
glutamate	glutamate	S_chemical	O
or	or	O	O
H2O2	h2o2	O	O
.	.	O	O

We	we	O	O
found	found	O	O
that	that	O	O
maltolyl	maltolyl	O	O
p-coumarate	p-coumarate	O	O
significantly	significantly	O	O
decreased	decreased	O	O
apoptotic	apoptotic	O	O
cell	cell	O	O
death	death	O	S_disease
and	and	O	O
reduced	reduced	O	O
reactive	reactive	B_chemical	O
oxygen	oxygen	S_chemical	O
species	species	I_chemical	O
,	,	O	O
cytochrome	cytochrome	O	O
c	c	O	O
release	release	O	O
,	,	O	O
and	and	O	O
caspase	caspase	B_chemical	O
3	3	I_chemical	O
activation	activation	O	O
.	.	O	O

Taking	taking	O	O
these	these	O	O
in	in	O	O
vitro	vitro	O	O
and	and	O	O
in	in	O	O
vivo	vivo	O	O
results	results	O	O
together	together	O	O
,	,	O	O
our	our	O	O
study	study	O	O
suggests	suggests	O	O
that	that	O	O
maltolyl	maltolyl	O	O
p-coumarate	p-coumarate	O	O
is	is	O	O
a	a	O	O
potentially	potentially	O	O
effective	effective	O	O
candidate	candidate	O	O
against	against	O	O
Alzheimer	alzheimer	O	B_disease
's	's	O	I_disease
disease	disease	O	I_disease
that	that	O	O
is	is	O	O
characterized	characterized	O	O
by	by	O	O
wide	wide	O	O
spread	spread	O	O
neuronal	neuronal	O	O
death	death	O	S_disease
and	and	O	O
progressive	progressive	O	O
decline	decline	O	O
of	of	O	O
cognitive	cognitive	O	O
function	function	O	O
.	.	O	O

